271 related articles for article (PubMed ID: 36119101)
1. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs.
Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K
Front Immunol; 2022; 13():982486. PubMed ID: 36119101
[TBL] [Abstract][Full Text] [Related]
2. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtyping for lung adenocarcinoma and a novel prognostic model based on ligand-receptor pairs.
Li D; Ma X; Ou S
Adv Med Sci; 2022 Sep; 67(2):316-327. PubMed ID: 36054998
[TBL] [Abstract][Full Text] [Related]
4. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
[TBL] [Abstract][Full Text] [Related]
5. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
6. Receptor-ligand pair typing and prognostic risk model for papillary thyroid carcinoma based on single-cell sequencing.
Cao ZX; Weng X; Huang JS; Long X
Front Immunol; 2022; 13():902550. PubMed ID: 35935973
[TBL] [Abstract][Full Text] [Related]
7. Turning up a new pattern: Identification of cancer-associated fibroblast-related clusters in TNBC.
Xie J; Zheng S; Zou Y; Tang Y; Tian W; Wong CW; Wu S; Ou X; Zhao W; Cai M; Xie X
Front Immunol; 2022; 13():1022147. PubMed ID: 36275659
[TBL] [Abstract][Full Text] [Related]
8. Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer.
Pu S; Zhou Y; Xie P; Gao X; Liu Y; Ren Y; He J; Hao N
Front Immunol; 2022; 13():964118. PubMed ID: 36059470
[TBL] [Abstract][Full Text] [Related]
9. Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy.
Yu B; Luo J; Yang Y; Zhen K; Shen B
J Gene Med; 2024 Jan; 26(1):e3645. PubMed ID: 38041540
[TBL] [Abstract][Full Text] [Related]
10. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
11. Identification of Ligand-Receptor Pairs Associated With Tumour Characteristics in Clear Cell Renal Cell Carcinoma.
Liu F; Wang P; Sun W; Jiang Y; Gong Q
Front Immunol; 2022; 13():874056. PubMed ID: 35734169
[TBL] [Abstract][Full Text] [Related]
12. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J; Zhang M; Tian Q; Yang J
Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer.
Cheng T; Wu Y; Liu Z; Yu Y; Sun S; Guo M; Sun B; Huang C
Front Immunol; 2022; 13():970950. PubMed ID: 36052076
[TBL] [Abstract][Full Text] [Related]
14. Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation.
Gou Q; Liu Z; Xie Y; Deng Y; Ma J; Li J; Zheng H
Front Pharmacol; 2022; 13():995555. PubMed ID: 36225561
[No Abstract] [Full Text] [Related]
15. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
[TBL] [Abstract][Full Text] [Related]
16. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
Zou Y; Xie J; Zheng S; Liu W; Tang Y; Tian W; Deng X; Wu L; Zhang Y; Wong CW; Tan D; Liu Q; Xie X
Int J Surg; 2022 Nov; 107():106936. PubMed ID: 36341760
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a ligand-receptor pairs signature to predict outcome and provide a therapeutic strategy in gastric cancer.
Yang W; Zhao X; Duan L; Niu L; Zhang Y; Zhou W; Li Y; Chen J; Fan A; Xie Q; Liu J; Han Y; Fan D; Hong L
Expert Rev Mol Diagn; 2023; 23(7):619-634. PubMed ID: 37248704
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
Liu Z; Ding M; Qiu P; Pan K; Guo Q
Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
[TBL] [Abstract][Full Text] [Related]
19. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer.
Chen X; Ren C; Zhou Z; Chen J; Fan X; Li X; Chen J; Zhu J
J Gene Med; 2024 Jan; 26(1):e3584. PubMed ID: 37605934
[TBL] [Abstract][Full Text] [Related]
20. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
